An adenylate cyclase inhibitor in the treatment of excited psychosis

✍ Scribed by Gregory Roitman; Joseph Levine; Yuly Bersudsky; R. H. Belmaker

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 112 KB
• Volume: 13
• Category: Article
• ISSN: 0885-6222
• DOI: 10.1002/(sici)1099-1077(199803)13:2<121::aid-hup961>3.0.co;2-b

✦ Synopsis

The authors examined the advantage of addition of the adenylate cyclase inhibitor demeclocycline (DMC) versus placebo to haloperidol therapy in the treatment of excited psychosis. Sixteen manic or excited schizoaective patients completed a double-blind controlled ®ve week trial. Nine patients were assigned to DMC and haloperidol and seven patients were assigned to placebo and haloperidol. Brief Psychiatric Rating Scale (BPRS) was used as an assessment tool at baseline, 1, 2, 3, 4 and 5 weeks. BPRS scores showed no signi®cant dierence between the two study groups. However, the reduction in BPRS score was 23 . 5 units in the DMC group and 16 . 7 units in the placebo group; power analysis showed that this trend would be signi®cant if the size of the study were doubled. Adenylate cyclase inhibitors might have a therapeutic role in the treatment of excited psychosis.